Regeneron Pharmaceuticals Inc (REGN)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Regeneron Pharmaceuticals Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 762.60 $ — 81% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 9.3% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 25
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 52.60 | 43.42 – 59.45 | 16,901 | 18.7% | 28 |
| 12/31/2027 | 50.21 | 42.52 – 57.25 | 18,311 | 13.5% | 10 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 8.06 | -20.90 | 3,789 | 10.30 | 24.20 | 1,263 | 996 |
| 2025: Q1 | 7.27 | 15.90 | 3,029 | -3.70 | 26.70 | 1,045 | 774 |
| 2025: Q2 | 12.81 | 3.20 | 3,676 | 3.60 | 37.90 | 1,144 | 968 |
| 2025: Q3 | 13.62 | 18.00 | 3,754 | 0.90 | 38.90 | 1,619 | 1,417 |
| 2025: Q4 | 7.86 | -2.60 | 3,884 | 2.50 | 21.70 | 1,171 | 922 |
| 2026: Q1 | 6.75 | -7.20 | 3,605 | 19.00 | 20.20 | 1,079 | 848 |
| 2026: Q2 | 12.23 | -4.50 | 4,291 | 16.70 | 30.20 | 813 | 813 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 4,860 | 1,331 | 896 | 7.70 | 1,486 | 4,449 | 6,973 |
| 2017 | 5,872 | 2,080 | 1,199 | 10.34 | 1,307 | 6,144 | 8,764 |
| 2018 | 6,711 | 2,534 | 2,444 | 21.29 | 2,195 | 8,757 | 11,735 |
| 2019 | 7,863 | 2,210 | 2,116 | 18.46 | 2,430 | 11,090 | 14,805 |
| 2020 | 8,497 | 3,577 | 3,513 | 30.52 | 2,618 | 11,025 | 17,163 |
| 2021 | 16,072 | 8,947 | 8,075 | 71.97 | 7,081 | 18,769 | 25,435 |
| 2022 | 12,173 | 5,386 | 4,338 | 38.22 | 5,015 | 22,664 | 29,215 |
| 2023 | 13,117 | 4,047 | 3,954 | 34.77 | 4,594 | 25,973 | 33,080 |
| 2024 | 14,202 | 3,991 | 4,413 | 38.34 | 4,421 | 29,354 | 37,759 |
| 2025 | 14,343 | 3,578 | 4,505 | 41.48 | 4,979 | 31,257 | 40,559 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Regeneron Pharmaceuticals, Inc. entdeckt, entwickelt, fertigt und kommerzialisiert weltweit Medikamente zur Behandlung diverser Krankheiten.
| Employees | 15,343 |
|---|---|
| Headquarters | Tarrytown, NY |
| Address | 777 Old Saw Mill River Road, 10591-6707 Tarrytown, United States |
| Phone | 914 847 7000 |
| Website | regeneron.com |
| IPO Date | 2. Apr 1991 |
| ISIN | US75886F1075 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Leonard S. Schleifer M.D., Ph.D. | Co-Founder, President, CEO & Co-Chairman | 1953 |
| George D. Yancopoulos M.D., Ph.D. | Co-Founder, President, Chief Scientific Officer & Co-Chairman | 1960 |
| Christopher R. Fenimore CPA | Executive VP of Finance & CFO | 1971 |
| Joseph J. LaRosa J.D. | Executive VP, General Counsel & Secretary | 1959 |
| Andrew J. Murphy Ph.D. | Executive VP of Research & Co-Chief Scientific Officer | 1958 |
| Daniel P. Van Plew | Executive VP and GM of Industrial Operations & Product Supply | 1973 |
| Rajesh Ahuja | Senior Vice President of Quality Assurance & Operations | – |
| Ryan Steinberger | Executive VP, Chief Digital & Technology Officer | – |
| Ryan Crowe | Senior Vice President of Investor Relations & Strategic Analysis | – |
| Melissa Lozner | Senior VP & Chief Compliance Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.